Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May 19;6(1):131-9.
doi: 10.11138/mltj/2016.6.1.131. eCollection 2016 Jan-Mar.

Efficacy of betamethasone valerate medicated plaster on painful chronic elbow tendinopathy: a double-blind, randomized, placebo-controlled trial

Antonio Frizziero  1 , Araldo Causero  2 , Stefano Bernasconi  3 , Rocco Papalia  4 , Mario Longo  5 , Vincenzo Sessa  6 , Francesco Sadile  7 , Pasquale Greco  8 , Umberto Tarantino  9 , Stefano Masiero  1 , Stefano Rovati  10 , Valeria Frangione  10
Affiliations

Efficacy of betamethasone valerate medicated plaster on painful chronic elbow tendinopathy: a double-blind, randomized, placebo-controlled trial

Antonio Frizziero et al. Muscles Ligaments Tendons J. .

Abstract

Objective: to investigate the efficacy and safety of a medicated plaster containing betamethasone valerate (BMV) 2.25 mg in patients with chronic elbow tendinopathy.

Methods: randomized, double-blind, placebo-controlled study with assignment 2:2:1:1 to BMV medicated plaster applied daily for 12 hours, daily for 24 hours or matched placebo. 62 patients aged ≥18 years with chronic lateral elbow tendinopathy were randomized. The primary efficacy variable was pain reduction (VAS) at day 28. Secondary objectives included summed pain intensity differences (SPID), overall treatment efficacy and tolerability.

Results: mean reduction in VAS pain score at day 28 was greater in both BMV medicated plaster groups, -39.35±27.69 mm for BMV12-h and -36.91±32.50 mm for BMV24-h, than with placebo, -20.20±27.32 mm. Considering the adjusted mean decreases, there was a statistically significant difference between BMV12-h and placebo (p=0.0110). Global pain relief (SPID) and overall treatment efficacy were significantly better with BMV. BMV and placebo plasters had similar local tolerability and there were few treatment-related adverse events.

Conclusions: BMV plaster was significantly more effective than placebo at reducing pain in patients with chronic elbow tendinopathies. The BMV plaster was safe and well tolerated.

Keywords: betamethasone valerate; chronic elbow tendinopathy; pain; topical corticosteroids; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart describing the progress of patients throughout the study. AE, adverse event; BMV, betamethasone medicated plaster; PP, per protocol; SAE, serious adverse event.
Figure 2
Figure 2
Pain reduction after 28 days of treatment with betamethasone valerate medicated plaster (BMV) or placebo plaster in 12-hour or 24-hour application regimens using a 0–100 mm visual analogue scale (VAS). Adjusted mean values from the ANCOVA models that included baseline VAS pain and study site as covariates. ITT, intention-to-treat; PP, per-protocol.
See this image and copyright information in PMC

References

    1. Smidt N, van der Windt DA. Tennis elbow in primary care. BMJ. 2006;333:927–928. - PMC - PubMed
    1. Ahmad Z, Siddiqui N, Malik SS, Abdus-Samee M, Tytherleigh-Strong G, Rushton N. Lateral epicondylitis: a review of pathology and management. Bone Joint J. 2013;95-B(9):1158–1164. - PubMed
    1. Allander E. Prevalence, incidence and remission rates of some common rheumatic diseases or syndromes. Scand J Rheumatol. 1974;3:145–153. - PubMed
    1. Calfee RP, Patel A, DaSilva MF, Akelman E. Management of lateral epicondylitis: current concepts. J Am Acad Orthop Surg. 2008;16:19–29. - PubMed
    1. Karkhanis S, Frost A, Maffulli N. Operative management of tennis elbow: a quantitative review. Br Med Bull. 2008;88(1):171–188. - PubMed